Targeted DNA RNA Sequencing Market Size, Share, Trends & Forecast, 2026-2034
REPORT DETAILS
Targeted DNA RNA Sequencing Market Summary
The global targeted DNA RNA sequencing market size was valued at USD 14.33 billion in 2025. The market is projected to grow from USD 17.09 billion in 2026 to USD 70.79 billion by 2034, exhibiting a CAGR of 19.40% during 2026–2034.
Market Statistics
Targeted DNA RNA Sequencing Market Key Takeaways
- North America dominated the global market with 42.1% share in 2025. The leading position is primarily driven by its advanced healthcare infrastructure.
- The Asia Pacific market is expected to exhibit the highest CAGR of 13.4% during the forecast period. The growth is driven by growing investments in healthcare infrastructure and the biotechnology sector.
- DNA-based sequencing held the largest share of 62.7% in 2025, due to its broad application in genomics.
- The exome sequencing segment accounted for the largest share of 34.8% in 2025. Its increased use in identifying disease-related genetic alterations boosts the segment dominance.
- The sequencing segment led the market with 56.9% revenue share in 2025. This is due to ongoing advancements in sequencing technologies.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What Is Targeted DNA RNA Sequencing? Definition, Target-Enrichment Methods & Clinical Applications
Targeted DNA/RNA Sequencing is one form of genetic testing. It refers to sequencing selected regions of DNA and RNA sequences instead of whole genome sequencing. The technology offers high depth genetic analysis at low costs. It makes data analysis easier. It is mostly used in cancer research and in diagnosing rare diseases. It is also being used more often in drug discovery, finding biomarkers, and precision medicine.
Several factors, including advancements in sequencing technologies that improve accuracy and reduce costs, the increasing prevalence of genetic disorders, and the growing demand for personalized medicine, drive the market growth. The rising adoption of next-generation sequencing (NGS) technologies, expansion of research in oncology and rare diseases, and the integration of sequencing data with other omics data to enhance diagnostic and therapeutic strategies are expected to emerge as key future trends in the market.
AI in Targeted DNA/RNA Sequencing: Variant Calling, Fusion Detection, FFPE QC & Clinical Interpretation
- Artificial intelligence is used to improve variant detection. It identifies clinically significant DNA and RNA mutations with higher accuracy.
- AI automates bioinformatics analysis. It reduces sequencing turnaround time. AI tools help minimize laboratory workload.
- In precision medicine and targeted therapy development, AI enhances biomarker discovery.
- AI tools offer faster genomic interpretation and personalized treatment recommendations. This supports clinical decision-making.
- AI enables automated quality control, data processing, and report generation. This streamlines sequencing workflows.
The global targeted DNA/RNA sequencing market focuses on sequencing specific regions of DNA or RNA to analyze genetic variations associated with various diseases and conditions.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
How Does Targeted DNA RNA Sequencing Work? Library Prep, Target Enrichment, Sequencing & Bioinformatics
- Biological samples like blood, tissue or saliva are obtained.
- DNA or RNA is isolated from biological samples.
- The necessary genes or genomic regions are enriched for study.
- Advanced sequencing technologies are used for the sequencing of selected regions.
- Bioinformatics software analyzes sequencing data.
- Genetic variants are also identified through sequencing process.
- Identified genetic variations are interpreted for clinical or research applications.
Targeted Panel vs Whole-Exome vs Whole-Genome Sequencing: Coverage, Depth, Cost & Use Cases
| Feature | Targeted Sequencing | Whole Genome Sequencing (WGS) |
| Coverage | Selected genes or genomic regions | Entire genome |
| Cost | Lower | Higher |
| Data Volume | Less complex and manageable | Large and highly complex datasets |
| Turnaround Time | Faster | More time-consuming |
| Primary Application | Specific genetic analysis and clinical diagnostics | Comprehensive genomic research and discovery |
Source: Polaris Market Research Analysis
Market Dynamics
Faster, Lower-Cost NGS Platforms Expand Targeted Sequencing Capacity
Advancements such as the development of next-generation sequencing (NGS) platforms enhance the speed, accuracy, and cost-effectiveness of sequencing. Companies such as Illumina and Thermo Fisher Scientific introduced high-throughput sequencers that can process millions of DNA/RNA sequences rapidly. According to a 2025 study published in Nature Reviews Genetics, the sequencing cost of a whole human genome has dropped to USD 600, a substantial reduction from $10,000 just a decade ago. This decline in cost is making targeted sequencing more accessible for research and clinical applications. Thus, recent advancements in sequencing technologies are significantly propelling the targeted DNA/RNA sequencing market growth.
Precision Oncology and Companion Diagnostics Increase Demand for Targeted Panels
Sequencing technologies are being increasingly used to identify genetic mutations and biomarkers that are crucial for cancer diagnosis, treatment, and prognosis. A 2025 report by the American Association for Cancer Research (AACR) highlights that targeted sequencing has led to the identification of over 200 cancer-related genes, which has enhanced the development of targeted therapies and personalized treatment plans. The precision in identifying specific mutations allows for more effective and tailored treatment approaches. Owing to all these advantages, targeted DNA RNA sequencing is highly used in oncology research. Hence, the rising oncology research is expected to drive the demand for targeted sequencing.
Multiomics Integration Links Targeted DNA/RNA Variants with Proteomic and Clinical Data
The integration of targeted DNA/RNA sequencing data with other omics data, such as proteomics and metabolomics, is emerging as a significant trend. This multi-omics approach provides a comprehensive view of the molecular mechanisms underlying diseases and facilitates more accurate diagnostics and treatment strategies. A 2025 article in Cell Systems reported that combining genomic data with proteomic profiles has improved the identification of disease pathways and potential therapeutic targets. The growing emphasis on holistic, multi-dimensional data analysis is pushing the development of more sophisticated data integration tools and algorithms, which is expected to enhance the capabilities and applications of targeted sequencing.
Key Growth Drivers & Market Challenges
| Growth Drivers | Market Challenges |
| Rising demand for precision medicine | High cost of sequencing equipment and assay design |
| Increasing cancer prevalence and oncology research | Complexity of downstream data interpretation |
| Falling sequencing costs (NGS whole-genome cost has dropped sharply over the past decade) | Shortage of skilled bioinformatics professionals |
| Expansion of molecular diagnostics and genetic testing | Data privacy concerns tied to genomic information |
| Advances in NGS platforms and assay chemistry | Regulatory variation across regions limiting standardization |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Technologies Used in Targeted Sequencing
Targeted DNA RNA sequencing includes different techniques and instruments. Advancements in targeted sequencing lead to lower costs and reduced times to obtain results.
| Technology | How It Works | Benefit | Key Application |
| Next-Generation Sequencing (NGS) | Sequences millions of DNA or RNA fragments in parallel across a targeted panel | High-throughput, faster turnaround, improved accuracy at scale | Large-scale genomic and clinical research programs |
| Amplicon Sequencing | PCR is used to amplify specific target regions before sequencing | Cost-effective, highly sensitive for known mutation hotspots | Targeted mutation detection, cancer profiling |
| Exome Sequencing | Captures and sequences only the protein-coding regions (exome) of the genome | Efficient variant detection without whole-genome cost | Rare disease research, disease-related variant identification |
Source: Polaris Market Research Analysis
Targeted DNA/RNA Sequencing Market Segmentation Analysis
Targeted DNA RNA Sequencing Market Assessment by Type
The targeted DNA RNA sequencing market, by type, is bifurcated into DNA-based and RNA-based. DNA-based sequencing held the largest share of 62.7% in 2025, largely due to its broad application in genomics, including cancer research, genetic disorder analysis, and pharmacogenomics. The widespread use of DNA-based sequencing is driven by its ability to provide comprehensive insights into genetic variations and mutations, which are critical for diagnosing and understanding various diseases. The segment benefits from established technologies and significant research investments, which further solidify its dominance in the market.
The RNA-based segment is experiencing a higher growth rate, driven by increasing interest in understanding gene expression and regulation at a more granular level. RNA sequencing provides valuable information on gene activity and is instrumental in fields such as transcriptomics and functional genomics. Recent advancements and reductions in sequencing costs have made RNA-based sequencing more accessible, leading to a surge in research and clinical applications. This growing focus on RNA analysis, particularly in cancer and rare diseases, is contributing to its rapid expansion in the market.
Comparison Matrix: DNA Sequencing vs. RNA Sequencing
| Feature | DNA Sequencing | RNA Sequencing |
| Focus | Genetic information | Gene expression patterns |
| Purpose | Detects genetic mutations and variants | Analyzes gene expression and transcript levels |
| Applications | Genetic disorders, oncology, inherited disease testing | Gene activity analysis, biomarker discovery, transcriptomics research |
| Data Type | DNA sequence variants | RNA expression profiles |
Source: Polaris Market Research Analysis
Targeted DNA RNA Sequencing Market Evaluation by Method
The targeted DNA/RNA sequencing market, based on method, is segmented into exome sequencing, enrichment sequencing, amplicon sequencing, and others. The exome sequencing segment accounted for the largest share of 34.8% in 2025. The method focuses on sequencing the coding regions of the genome, which are crucial for understanding genetic variations associated with diseases. Exome sequencing is widely adopted due to its ability to efficiently identify mutations and variants in protein-coding genes, making it a preferred choice for genetic research and clinical diagnostics. Its established use in identifying disease-related genetic alterations ensures its continued dominance in the market.
The enrichment sequencing segment is currently registering the highest growth, reflecting its increasing application in targeted research and clinical diagnostics. This method enhances the detection of specific genomic regions by selectively capturing and sequencing them, thus improving the sensitivity and accuracy of the results. The rise in precision medicine and the need for more focused genetic analysis have driven the demand for enrichment sequencing methods. Its ability to tailor the sequencing process to specific genetic targets aligns with the growing emphasis on personalized medicine, contributing to its rapid expansion in the market.
Targeted DNA RNA Sequencing Market Breakdown by Workflow
In terms of workflow, the targeted DNA RNA sequencing market is segmented into pre-sequencing, sequencing, and data analysis. The sequencing segment led the market with 56.9% revenue share in 2025 due to its central role in the sequencing process. This segment encompasses the actual process of reading genetic sequences and is critical for obtaining the data needed for subsequent analysis. The dominance of this segment is supported by the continuous advancements in sequencing technologies, such as next-generation sequencing (NGS), which enhance the accuracy and efficiency of genetic data acquisition. The widespread use and ongoing improvements in sequencing technologies solidify its leading position in the market.
The data analysis segment is experiencing the highest growth, driven by the increasing complexity of genomic data and the rising need for advanced analytical tools. As the volume of sequencing data expands, sophisticated bioinformatics solutions and software are essential for interpreting and integrating this information. The rise in personalized medicine and the integration of multi-omics data are contributing to the heightened demand for robust data analysis solutions. This segment's rapid development reflects the growing importance of effective data interpretation in leveraging the full potential of targeted sequencing technologies.
Targeted DNA RNA Sequencing Market Breakdown by End User
The targeted DNA/RNA sequencing market, by end user, is segmented into academic research, hospitals & clinics, pharma & biotech entities, and others. The academic research segment holds the largest market share, reflecting its extensive use in fundamental and applied genetic research. Academic institutions leverage targeted sequencing technologies to advance understanding of genetic mechanisms, explore disease pathways, and develop new therapeutic approaches. The robust investments in research and the high volume of genomic studies conducted in academic settings contribute to the segment's dominance, supported by continuous funding and grant opportunities.
The pharma & biotech entities segment is experiencing the highest growth, driven by increasing investments in drug development and personalized medicine. Pharmaceutical and biotechnology companies utilize targeted sequencing for drug discovery, biomarker identification, and the development of tailored therapeutic strategies. The segment's rapid expansion is fueled by the need for precise genomic insights to enhance drug efficacy and safety profiles, alongside the growing trend of integrating genomic data into clinical trials and drug development processes.
Applications of Targeted DNA/RNA Sequencing
Targeted sequencing supports a wide range of research and clinical use cases. It is adopted for different applications right from early-stage drug discovery to point-of-care diagnostics.
| Application Area | Key Uses |
| Clinical Diagnostics | Genetic disease testing, infectious disease identification, molecular-level disease confirmation to support treatment planning |
| Cancer Research | Tumor mutation detection, cancer biomarker discovery, treatment selection, companion diagnostics for precision oncology |
| Precision Medicine | Personalized treatment selection, improved diagnostic accuracy, patient stratification for targeted therapy development |
| Drug Discovery | Drug target identification, clinical trial patient response analysis, biomarker validation for therapeutic development |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Targeted DNA RNA Sequencing Market Share by Region
By region, the study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market with 42.1% share in 2025, primarily due to its advanced healthcare infrastructure, high research funding, and significant investments in genomics and biotechnology. The region benefits from the presence of leading sequencing technology companies, robust academic and clinical research facilities, and a well-established healthcare system that supports innovative genetic research and personalized medicine. North America's dominance is further supported by its early adoption of advanced sequencing technologies and a strong emphasis on precision medicine.
In Europe, the targeted DNA/RNA sequencing market is experiencing steady growth, driven by significant investments in research and development and a strong focus on precision medicine. The European Union’s Horizon Europe program and various national research initiatives have increased funding for genomic studies, facilitating advancements in sequencing technologies and applications. Countries such as Germany, the UK, and France are at the forefront, with numerous academic institutions and biotech companies engaged in cutting-edge research. Additionally, Europe’s well-established regulatory framework and collaborative research networks contribute to a conducive environment for market expansion.
The Asia Pacific market is expected to exhibit the highest CAGR of 13.4% during the forecast period is witnessing rapid growth, driven by increasing investments in healthcare infrastructure and the biotechnology sector, coupled with a growing emphasis on personalized medicine. Countries such as China and India are emerging as significant players due to their large population base, expanding healthcare needs, and rising research activities. The region benefits from a burgeoning biotech sector, improved research facilities, and government initiatives supporting genomic research. However, the market faces challenges related to diverse healthcare systems, regulatory variations, and varying levels of access to advanced sequencing technologies across different countries in the region. Despite these challenges, the rapid growth in research activities and healthcare investments positions Asia Pacific as a key region for future market expansion.
Source: Polaris Market Research Analysis
Key Players and Competitive Analysis Report
Key players in the targeted DNA/RNA sequencing market are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, Roche Sequencing Solutions, and QIAGEN. Other significant companies are Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Genomatix Software, and Bio-Rad Laboratories. Notable players also include PerkinElmer, Hudon Alpha, Element Biosciences, and Twist Bioscience. Additionally, companies such as Nextera and LGC Biosearch Technologies are actively contributing to market advancements. These companies remain active in the market, providing a range of products and services related to DNA/RNA sequencing technologies.
In terms of competitive analysis, Illumina Inc. and Thermo Fisher Scientific are prominent players due to their extensive product portfolios and strong market presence. They are well-positioned to capitalize on the growing demand for sequencing technologies owing to their advanced platforms and broad customer base. Agilent Technologies and Roche Sequencing Solutions also play significant roles by offering innovative solutions and investing in research to enhance their product offerings. These companies are distinguished by their continuous innovation and robust support networks, which contribute to their strong market positions.
The market dynamics are shaped by intense competition among these players, each striving to develop more accurate and cost-effective sequencing solutions. The competition drives technological advancements, resulting in improved performance and reduced costs of sequencing services. Additionally, the focus on strategic collaborations, partnerships, and acquisitions by these companies enhances their competitive edge and ability to address evolving market needs. Overall, the market is characterized by a high level of innovation and strategic activity, which influences the competitive landscape and shapes future growth trajectories.
Illumina Inc. is a global player in the targeted DNA/RNA sequencing market, known for its comprehensive range of sequencing platforms and reagents. The company focuses on providing high-throughput sequencing solutions that cater to various research and clinical applications.
Thermo Fisher Scientific is another significant player, offering a wide array of sequencing technologies and solutions. The company supports diverse applications in genomics through its sequencing platforms, reagents, and software.
Key Companies in the Targeted DNA RNA Sequencing Market
- Illumina Inc.
- Thermo Fisher Scientific
- Agilent Technologies
- Roche Sequencing Solutions
- QIAGEN
- Pacific Biosciences
- Oxford Nanopore Technologies
- BGI Genomics
- Genomatix Software
- Bio-Rad Laboratories
- PerkinElmer
- Hudon Alpha
- Element Biosciences
- Twist Bioscience
- Nextera
Future Outlook of Targeted DNA RNA Sequencing Market
The targeted DNA RNA sequencing industry is expected to expand in the coming years. Healthcare and research organizations are increasingly adopting precision genomics and molecular diagnostics approaches. Also, preference for personalized medicine is expected to rise to treat various conditions. Innovations in NGS platforms and AI-driven bioinformatics would boost the market expansion. Also, lower sequencing costs and expanding applications in oncology, rare diseases, and drug development would fuel the growth.
Targeted DNA RNA Sequencing Market Developments
- June 2026: Roche launched AXELIOS 1, a NGS platform. AXELIOS 1 is powered by innovative SBX technology. The platform is designed for research workflows. It is capable of end-to-end, same-day whole-genome sequencing. It will offer accurate results within hours. (Source: roche.com)
- In February 2025, Roche of Switzerland introduced its SBX sequencing platform, providing ultra-rapid, scalable next-generation sequencing to speed genomic research, improve clinical uses, and reinforce its competitive standing in precision medicine markets.
Targeted DNA RNA Sequencing Market Segmentation
By Type Outlook (Revenue – USD Billion, 2021–2034)
- RNA-Based
- DNA-Based
By Method Outlook (Revenue – USD Billion, 2021–2034)
- Exome Sequencing
- Enrichment Sequencing
- Amplicon Sequencing
- Others
By Workflow Outlook (Revenue – USD Billion, 2021–2034)
- Pre-sequencing
- Sequencing
- Data Analysis
By End User Outlook (Revenue – USD Billion, 2021–2034)
- Academic Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Others
By Regional Outlook (Revenue – USD Billion, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Targeted DNA RNA Sequencing Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 14.33 billion |
| Market Size Value in 2026 | USD 17.09 billion |
| Revenue Forecast by 2034 | USD 70.79 billion |
| CAGR | 19.40% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Targeted DNA RNA Sequencing Market FAQ's
The global targeted DNA RNA sequencing market size was valued at USD 14.33 billion in 2025 and is projected to grow to USD 70.79 billion by 2034.
The global market is projected to register a CAGR of 19.40% during the forecast period.
North America dominated the global market, accounting for the largest share of 42.1% in 2025.
A few key players in the targeted DNA/RNA sequencing market are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, Roche Sequencing Solutions, and QIAGEN. Other significant companies are Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Genomatix Software, and Bio-Rad Laboratories.
The DNA-based sequencing segment accounted for the largest market share of 62.7% in 2025, driven by its widespread adoption in genomic research and molecular diagnostics.
The exome sequencing segment accounted for the largest market share of 34.8%, driven by the growing adoption of exome sequencing for genetic disorder diagnosis and research applications.
Targeted DNA sequencing is used for cancer mutation profiling and rare disease diagnosis. It is also preferred for inherited disorder testing, pharmacogenomics, and companion diagnostics. This is also adopted in biomarker discovery and precision medicine. The targeted sequencing analyzes specific genes of clinical importance.
RNA sequencing is utilized in studying gene expression and discovering new transcripts. The process allows finding biomarkers and studying the mechanisms of diseases. The sequencing analyzes the reaction to drugs. RNA sequencing has applications in cancer, infectious diseases, and precision medicine.
The process of targeted sequencing identifies genetic mutations within cancers. The technology involved with targeted sequencing helps in carrying out diagnoses and identifying biomarkers. It is helpful in finding the right treatment for diseases.
Download Sample Report of Targeted DNA RNA Sequencing Market
Please fill out the form to request a customized copy of the research report.
